Featured Research

from universities, journals, and other organizations

Mortality Rate Is Twice As High In Patients With Pneumonia Caused By Highly Resistant Bacteria

Date:
August 29, 2006
Source:
BioMed Central
Summary:
Patients suffering from hospital-acquired pneumonia caused by a type of bacteria that is highly resistant to virtually all antibiotics are twice as likely to die as patients infected with other, less resistant bacteria. A study published in the journal Critical Care shows for the first time that the highly resistant, metallo-beta-lactamase-producing Pseudomonas aeruginosa is associated with a much higher mortality rate than other types of the bacteria in patients with hospital-acquired pneumonia.

Patients suffering from hospital-acquired pneumonia caused by a type of bacteria that is highly resistant to virtually all antibiotics are twice as likely to die as patients infected with other, less resistant bacteria.

A study published recently in the journal Critical Care shows for the first time that the highly resistant, metallo-beta-lactamase-producing Pseudomonas aeruginosa is associated with a much higher mortality rate than other types of the bacteria in patients with hospital-acquired pneumonia. The authors conclude that this may be due to the use of inappropriate antimicrobial treatments for infections with metallo-beta-lactamase-producing P. aeruginosa, and suggest that therapeutic approaches should be reviewed in hospitals with high prevalence of the bacteria.

Alexandre Zavascki from Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil, and colleagues from other institutions in Brazil studied 150 patients admitted to two hospitals in Porto Alegre and suffering from hospital-acquired pneumonia.

The results of Zavascki et al.'s study show that 42 patients were infected with metallo-beta-lactamase-producing P. aeruginosa. For these patients, the 30-day mortality rate was 57.1%, compared with 29.6% for patients infected with other P. aeruginosa strains. Only half of the patients infected with the highly resistant bacteria were treated with appropriate antibiotics. But even when the recommended treatment was used, mortality was still high, suggesting that the optimal treatment for these highly resistant bacteria is yet to be found.

Article: Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-b-lactamases-mediated multidrug resistance: a prospective observational study." Alexandre P Zavascki, Afonso L Barth, Juliana F Fernandez, Ana Lucia D Moro, Ana Lucia S Goncalves and Luciano Z Goldani. Critical Care 2006, in press


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Cite This Page:

BioMed Central. "Mortality Rate Is Twice As High In Patients With Pneumonia Caused By Highly Resistant Bacteria." ScienceDaily. ScienceDaily, 29 August 2006. <www.sciencedaily.com/releases/2006/08/060829081755.htm>.
BioMed Central. (2006, August 29). Mortality Rate Is Twice As High In Patients With Pneumonia Caused By Highly Resistant Bacteria. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/08/060829081755.htm
BioMed Central. "Mortality Rate Is Twice As High In Patients With Pneumonia Caused By Highly Resistant Bacteria." ScienceDaily. www.sciencedaily.com/releases/2006/08/060829081755.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins